Inspire Investing Hits $3 Billion AUM
"We are incredibly excited and grateful to reach this milestone," said
As of
About Inspire Investing
Inspire Investing is the world's largest provider of faith-based ETFs and creator of the globally recognized Inspire Impact Score™, which investors worldwide use to measure the alignment of their investments according to Biblically Responsible Investing (BRI) principles. Inspire has ranked as one of America's Top RIAs by FA Magazine eight times since 2017, making the "Top 50 fastest growing RIA firms" three years in a row. Inspire was also recognized in The Financial Times "
Inspire donates 50% of its net corporate profits to support impactful ministry projects around the globe through its Give50 Program. Most recently, Inspire completed a 3-year village transformation project in the coffee farming mountains of
To learn more about the Give50 program, please visit www.inspireinvesting.com/give50.
Visit www.inspireinvesting.com to learn more about Inspire's biblically responsible investment products.
Investing involves risk. Past performance does not guarantee future results. There is no guarantee that the funds will achieve their objective, generate positive returns, or avoid losses.
BEFORE INVESTING, CONSIDER THE FUNDS' INVESTMENT OBJECTIVES, RISKS, CHARGES AND EXPENSES. TO OBTAIN A PROSPECTUS OR SUMMARY PROSPECTUS WHICH CONTAINS THIS AND OTHER INFORMATION, CALL 877.658.9473, OR VISIT WWW.INSPIREETF.COM. READ IT CAREFULLY.
Inspire ETFs are distributed by Foreside Financial Services LLC, Member FINRA.
Inspire and Foreside Financial Services LLC are not affiliated.
Investment advisory services offered through Inspire Investing, LLC, a Registered Investment Advisor with the SEC.
View original content to download multimedia:https://www.prnewswire.com/news-releases/inspire-investing-hits-3-billion-aum-302270963.html
SOURCE Inspire Investing
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA grants accelerated approval to Ultragenyx gene therapy for GSDIa
- Biodexa reaches 50% enrollment in Phase 3 FAP trial
- EShallGo prices $1.75M registered direct offering at $1 per share
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share